Every earnings call announcement on NSE and BSE that our alert engine sent, newest first. Each one has its own page with the summary, the key figures and the original filing.
Endurance reported strong FY26 revenue growth but faces near-term EBITDA pressure from commodity inflation and energy spikes. Management is aggressively pivoting to EV-specific components and higher-value technology products like ABS.
Park Medi World delivered record FY26 results with Revenue up 21% to ₹1,679cr and PAT up 27% to ₹274cr, driven by record patient volumes and capacity expansion.
SPR Auto Technologies (formerly Shriram Pistons) reported a landmark FY26 with record total income of ₹4,571cr and EBITDA of ₹989cr, driven by acquisitions and strong domestic demand.
Bank of India reported a strong FY26 with Net Profit rising 14% YoY to ₹10,527 crore. Strategy focuses on RAM book expansion (target 62%) and improving domestic NIM towards 3%.
Aakaar Medical Technologies reported H2FY26 revenue of ₹41.6 Cr and PAT of ₹7.4 Cr, successfully pivoting to higher-margin owned brands and cash-first billing.
Aurionpro's FY26 revenue grew 20.2% to ₹1,411 Cr, but missed internal 30% targets due to Middle East (MEA) geopolitical delays and hyperscaler project shifts. Strategy focuses on AI-native Banking and Transit stacks.
Hester Biosciences delivered a strong Q3 FY26 with standalone revenue up 12% and PAT up 140%, driven by robust Poultry Healthcare performance and operational leverage despite Animal Healthcare headwinds.
Rashi Peripherals delivered record FY26 revenues driven by a generational PC refresh cycle and AI infrastructure demand, though margins remain razor-thin as a value-added distributor.
Medanta delivered a robust FY26 with 20% revenue growth, driven by rapid ramp-up in Noida and maturity in Lucknow/Patna. Management is balancing high-intensity expansion with maintained 24-25% EBITDA margins.
Atlanta Electricals delivered a defining FY26 with robust revenue growth and significant margin expansion driven by a richer 220KV product mix and new capacity at the Vadod facility.
Persistent delivered $1,654.4M revenue in FY26 (+17.4% YoY) with an AI-led strategy. Q4 FY26 marked the 24th sequential quarter of growth with EBIT margin at 16.3%.
Artemis Medicare delivered strong FY26 results with consolidated revenue of ₹1,081 Cr, up 15.4% YoY. Strategy focuses on expanding bed capacity and high-end quaternary care.
CARE Ratings delivered strong FY26 performance with consolidated revenue growing 18% to ₹473cr and PAT up 24% to ₹174cr. The company is pivoting towards AI-driven analytics and expanding its global rating footprint.
Vishal Mega Mart delivered strong FY26 results with a focus on private label dominance and aggressive tier-2/3 expansion despite rising inflationary pressures.
Advanced Enzyme reported its highest-ever quarterly and annual revenue for FY26. Management focused on expanding R&D, human healthcare flagship growth, and navigating global supply chain disruptions.
United Spirits (Diageo India) reported 7.6% Total NSV growth and 8.6% P&A NSV growth for FY26, driven by premiumization and portfolio re-shaping under 'Three Indias' strategy.
Solar Industries delivered stellar FY26 performance with 30% revenue growth and 35% PAT growth. Management issued strong FY27 guidance targeting ₹14,000cr revenue, driven by defense and international markets.
Cholamandalam MS General Insurance (subsidiary) reported Q4 FY26 GDPI of ₹2,048cr and PBT of ₹454cr, focusing on motor car segments and non-crop business expansion.
Alembic Pharma reported Q4FY26 revenue of INR 18.48 Bn, up 4% YoY, and PAT of INR 2.03 Bn, up 29% YoY. The company launched its first branded product, Pivya, in the US.
Apex Ecotech delivered record FY26 results, driven by large-scale project execution and rising demand for zero liquid discharge solutions in the water treatment sector.
Nava Ltd reported FY26 consolidated revenue of ₹4,479 Cr (+8.3% YoY) and PAT of ₹1,039 Cr (-27.6% YoY). Standalone performance reached record highs driven by strong operations and investment cashflows.
Sai Life Sciences delivered strong FY26 performance with 29% revenue growth and 56% EBITDA growth, driven by expansion in CDMO and CRO segments and improved operating leverage.